SciBac creates rEvolutionary live biotherapeutics that treat and prevent antibiotic resistant disease in the respiratory tract and beyond. We improve beneficial bacteria using our novel MERGE (Microbial Enhanced Recombinants Generated by Evolution) platform that can naturally and safely transfer and/or create useful traits including stability in scale-up. Our pipeline includes biofilm and anti-infective solutions for chronic infections in cystic fibrosis (CF) patients for Psuedomonas and Non-tuberculous Mycobacteria (NTM). We are a preclinical company. Covid-19 therapies are possible as an anti-inflammatory, mucolytic that prevents secondary infections without antibiotics.